Influence of Genetics Polymorphism of OATP2B1Transporter on Montelukast Response in Samples of Asthmatic Children

Abstract

Objectives: The primary objectives are to evaluate the impact of OATP2B1c.935G>A (rs12422149) genetic polymorphisms on montelukast treatment responses in children with asthma in Iraq. Methods and patients: This observational cross_sectional study was conducted from the beginning of October  2022  up to the  ending  of  September  2023  at the respiratory  clinic centre of the Karbalaa Hospital for Children.One hundred participants, both male and female, aged between six and fifteen, who had been  taking  montelukast  as  a control  medication on a  daily basis for  at least  a month, were   included in the study.Following DNA extraction, allele_specific PCR  was performed to identify the genotypes of the various patients. Measurements of total serum IgE, the Asthma Control Test(ACT), and the Pulmonary Function Tests (PEF and FEV1) were made. Results: Genetic amplification results indicate that the distribution of the polymorphism of the c.935G>A gene was 48% in GG wild homozygous, 45% in GA mutant heterozygous, and 7% in mutant homozygous AA. Patients with mutant genes (GA and AA) exhibit high total IgE, low  PEF and  FEV1, and  <19  ACT scores. This polymorphism is expected to have a significant association (p value<0.05)withmontelukast responsiveness. Conclusions:  A significant association, was  seen between the montelukast response and the OATP2B1 c.935 G>A genetic polymorphism.